Seegene INC.
Jun Yong Ha has a diverse work experience spanning over several years. Jun Yong has held various leadership positions in reputable companies such as Seegene Inc., Access Bio Inc., and Princeton University. Currently, they serve as the VP of R&D at Seegene Inc., where they lead product development and clinical study for the US market. Jun Yong has also worked as an Independent Consultant and Director of R&D at Access Bio Inc., where they directed product development, clinical trials, and regulatory clearance/authorization. Previously, they held roles such as Head of R&D Division and General Manager at Access Bio Inc., where they focused on developing in vitro diagnostics for infectious diseases. Additionally, they have worked as a Senior Scientist at Princeton University, where they mentored students, conducted research, and managed lab operations. Prior to that, they worked as a Consultant at Signum Biosciences and a Senior Specialist at AmorePacific co. Overall, Jun Yong Ha has a strong background in R&D and extensive experience in various aspects of product development, clinical trials, and regulatory affairs.
Jun Yong Ha obtained a Bachelor's Degree in an unspecified field of study from Seoul National University in 1994. Jun then went on to earn a Master's Degree in Organic Chemistry from the same university in 1996. Continuing their education, Jun completed a Doctor of Philosophy (Ph.D.) in Biochemistry/Structural Biology at Seoul National University from 2002 to 2007. There is no information available regarding any certifications obtained by Jun.
This person is not in any teams
Seegene INC.
1 followers
[INTRODUCING OUR COMPANY] The people of Seegene are on a purposeful mission to improve the world we live in. We aim to improve the quality of life for everyone globally by bringing molecular diagnostics to the masses. Molecular diagnostics is the most effective method to accurately diagnose ailments and is also the best way to diagnose them early which is when you can make the most difference in the recovery treatment. With industry-leading IP in molecular diagnostics reagent assays, we are dedicated to leveraging our unique technologies to increase our product portfolio, expand our market coverage, and lowering the total cost to serve our customers so that molecular diagnostics become a part of the fabric of everyone’s life and thus, improving the quality of life for everyone in the world. [OUR HISTORY AND OUR FUTURE] Since our founding in 2000, we have been steadfastly focused on molecular diagnostics. Currently, our product portfolio consists of over 250 molecular diagnostics reagent kits as well as a wide range of instruments and consumables that are sold globally. Testament to our expertise, when the pandemic started, Seegene was one of the first companies in the world to provide testing kits that were crucial in the fight against COVID. Today, we are a company with revenue of over $1 billion dollars and 65% gross margins. With 8 overseas entities, we generate a majority of our revenue outside of Korea. In keeping with our spirit of innovation and making a difference in the world, there are many exciting innovations being worked on at Seegene which will make it easier for the world to access the benefits of molecular diagnostics. We are transforming our business from a discrete reagent assay and instruments business to a platform business that will create new markets for molecular diagnostics and improve the quality of life for everyone. We hope that you will join us in our mission to make a meaningful difference in the world.